Romanelli Filippo, Corbo AnthonyMarco, Salehi Maryam, Yadav Manisha C, Salman Soha, Petrosian David, Rashidbaigi Omid J, Chait Jesse, Kuruvilla Jes, Plummer Maria, Radichev Ilian, Margulies Kenneth B, Gerdes A Martin, Pinkerton Anthony B, Millán José Luis, Savinov Alexei Y, Savinova Olga V
Department of Biomedical Sciences, New York Institute of Technology College of Osteopathic Medicine, Old Westbury, New York, United States of America.
Children's Health Research Center, Sanford Research, Sioux Falls, South Dakota, United States of America.
PLoS One. 2017 Oct 12;12(10):e0186426. doi: 10.1371/journal.pone.0186426. eCollection 2017.
Overexpression of tissue-nonspecific alkaline phosphatase (TNAP) in endothelium leads to arterial calcification in mice. The purpose of this study was to examine the effect of elevated endothelial TNAP on coronary atherosclerosis. In addition, we aimed to examine endogenous TNAP activity in human myocardium.
A vascular pattern of TNAP activity was observed in human non-failing, ischemic, and idiopathic dilated hearts (5 per group); no differences were noted between groups in this study. Endothelial overexpression of TNAP was achieved in mice harboring a homozygous recessive mutation in the low density lipoprotein receptor (whc allele) utilizing a Tie2-cre recombinase (WHC-eTNAP mice). WHC-eTNAP developed significant coronary artery calcification at baseline compared WHC controls (4312 vs 0μm2 alizarin red area, p<0.001). Eight weeks after induction of atherosclerosis, lipid deposition in the coronary arteries of WHC-eTNAP was increased compared to WHC controls (121633 vs 9330μm2 oil red O area, p<0.05). Coronary lesions in WHC-eTNAP mice exhibited intimal thickening, calcifications, foam cells, and necrotic cores. This was accompanied by the reduction in body weight and left ventricular ejection fraction (19.5 vs. 23.6g, p<0.01; 35% vs. 47%, p<0.05). In a placebo-controlled experiment under atherogenic conditions, pharmacological inhibition of TNAP in WHC-eTNAP mice by a specific inhibitor SBI-425 (30mgkg-1d-1, for 5 weeks) reduced coronary calcium (78838 vs.144622μm2) and lipids (30754 vs. 77317μm2); improved body weight (22.4 vs.18.8g) and ejection fraction (59 vs. 47%). The effects of SBI-425 were significant in the direct comparisons with placebo but disappeared after TNAP-negative placebo-treated group was included in the models as healthy controls.
Endogenous TNAP activity is present in human cardiac tissues. TNAP overexpression in vascular endothelium in mice leads to an unusual course of coronary atherosclerosis, in which calcification precedes lipid deposition. The prevalence and significance of this mechanism in human atherosclerosis requires further investigations.
内皮组织非特异性碱性磷酸酶(TNAP)的过表达会导致小鼠动脉钙化。本研究旨在探讨内皮TNAP升高对冠状动脉粥样硬化的影响。此外,我们旨在检测人类心肌中的内源性TNAP活性。
在人类非衰竭、缺血和特发性扩张型心脏(每组5例)中观察到TNAP活性的血管模式;本研究中各实验组间未观察到差异。利用Tie2-cre重组酶在低密度脂蛋白受体中存在纯合隐性突变(whc等位基因)的小鼠中实现TNAP的内皮过表达(WHC-eTNAP小鼠)。与WHC对照组相比,WHC-eTNAP小鼠在基线时出现显著的冠状动脉钙化(茜素红面积:4312 vs 0μm2,p<0.001)。动脉粥样硬化诱导8周后,与WHC对照组相比,WHC-eTNAP小鼠冠状动脉中的脂质沉积增加(油红O面积:121633 vs 9330μm2,p<0.05)。WHC-eTNAP小鼠的冠状动脉病变表现为内膜增厚、钙化、泡沫细胞和坏死核心。这伴随着体重和左心室射血分数的降低(19.5 vs. 23.6g,p<0.01;35% vs. 47%,p<0.05)。在致动脉粥样硬化条件下的安慰剂对照实验中,用特异性抑制剂SBI-425(30mgkg-1d-1,持续5周)对WHC-eTNAP小鼠进行TNAP的药理学抑制,可减少冠状动脉钙化(78838 vs.144622μm²)和脂质(30754 vs. 77317μm²);改善体重(22.4 vs.18.8g)和射血分数(59 vs. 47%)。SBI-425的作用在与安慰剂的直接比较中具有显著性,但在将TNAP阴性的安慰剂治疗组作为健康对照纳入模型后消失。
内源性TNAP活性存在于人类心脏组织中。小鼠血管内皮中TNAP的过表达导致冠状动脉粥样硬化的异常进程,其中钙化先于脂质沉积。这种机制在人类动脉粥样硬化中的发生率和意义需要进一步研究。